Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
BIOCON | GLENMARK PHARMA | BIOCON / GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.6 | 15.1 | 209.9% | View Chart |
P/BV | x | 3.8 | 2.5 | 152.3% | View Chart |
Dividend Yield | % | 0.3 | 0.4 | 64.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
GLENMARK PHARMA Mar-19 |
BIOCON / GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 712 | 99.4% | |
Low | Rs | 554 | 484 | 114.5% | |
Sales per share (Unadj.) | Rs | 91.9 | 349.6 | 26.3% | |
Earnings per share (Unadj.) | Rs | 16.7 | 32.8 | 51.0% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 44.3 | 54.5% | |
Dividends per share (Unadj.) | Rs | 1.00 | 2.00 | 50.0% | |
Dividend yield (eoy) | % | 0.2 | 0.3 | 47.4% | |
Book value per share (Unadj.) | Rs | 101.6 | 198.6 | 51.2% | |
Shares outstanding (eoy) | m | 600.00 | 282.17 | 212.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 1.7 | 401.4% | |
Avg P/E ratio | x | 37.7 | 18.2 | 207.0% | |
P/CF ratio (eoy) | x | 26.1 | 13.5 | 193.5% | |
Price / Book Value ratio | x | 6.2 | 3.0 | 206.2% | |
Dividend payout | % | 6.0 | 6.1 | 98.1% | |
Avg Mkt Cap | Rs m | 378,330 | 168,625 | 224.4% | |
No. of employees | `000 | 6.1 | 12.0 | 50.9% | |
Total wages/salary | Rs m | 11,653 | 20,561 | 56.7% | |
Avg. sales/employee | Rs Th | 8,994.3 | 8,196.0 | 109.7% | |
Avg. wages/employee | Rs Th | 1,900.7 | 1,708.1 | 111.3% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 768.5 | 212.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 98,655 | 55.9% | |
Other income | Rs m | 1,444 | 2,081 | 69.4% | |
Total revenues | Rs m | 56,588 | 100,736 | 56.2% | |
Gross profit | Rs m | 15,883 | 15,858 | 100.2% | |
Depreciation | Rs m | 4,478 | 3,259 | 137.4% | |
Interest | Rs m | 709 | 3,346 | 21.2% | |
Profit before tax | Rs m | 12,140 | 11,335 | 107.1% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
Tax | Rs m | 2,123 | 3,756 | 56.5% | |
Profit after tax | Rs m | 10,026 | 9,250 | 108.4% | |
Gross profit margin | % | 28.8 | 16.1 | 179.2% | |
Effective tax rate | % | 17.5 | 33.1 | 52.8% | |
Net profit margin | % | 18.2 | 9.4 | 193.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 66,968 | 72.0% | |
Current liabilities | Rs m | 30,376 | 40,211 | 75.5% | |
Net working cap to sales | % | 32.4 | 27.1 | 119.4% | |
Current ratio | x | 1.6 | 1.7 | 95.3% | |
Inventory Days | Days | 68 | 83 | 82.0% | |
Debtors Days | Days | 86 | 81 | 105.3% | |
Net fixed assets | Rs m | 64,130 | 33,322 | 192.5% | |
Share capital | Rs m | 3,000 | 282 | 1,063.1% | |
"Free" reserves | Rs m | 57,980 | 55,770 | 104.0% | |
Net worth | Rs m | 60,980 | 56,052 | 108.8% | |
Long term debt | Rs m | 15,766 | 35,738 | 44.1% | |
Total assets | Rs m | 121,924 | 132,888 | 91.7% | |
Interest coverage | x | 18.1 | 4.4 | 413.0% | |
Debt to equity ratio | x | 0.3 | 0.6 | 40.6% | |
Sales to assets ratio | x | 0.5 | 0.7 | 60.9% | |
Return on assets | % | 8.8 | 9.5 | 92.9% | |
Return on equity | % | 16.4 | 16.5 | 99.6% | |
Return on capital | % | 16.8 | 17.8 | 94.0% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 62,998 | 24.6% | |
Fx outflow | Rs m | 10,399 | 22,859 | 45.5% | |
Net fx | Rs m | 5,107 | 40,140 | 12.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 13,242 | 87.2% | |
From Investments | Rs m | -7,138 | -6,990 | 102.1% | |
From Financial Activity | Rs m | -2,417 | -7,387 | 32.7% | |
Net Cashflow | Rs m | 2,103 | -2,971 | -70.8% |
Indian Promoters | % | 40.4 | 48.3 | 83.6% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 6.9 | 121.7% | |
FIIs | % | 10.7 | 34.4 | 31.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 10.5 | 189.5% | |
Shareholders | 109,995 | 56,727 | 193.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE FULFORD INDIA ASTRAZENECA PHARMA DIVIS LABORATORIES
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More